Harmony Biosciences Holdings (HRMY)

Nov 11, 2026

Harmony Biosciences Holdings Inc. reported a decline in third-quarter profit to $48.2 million, or 81 cents per diluted share, despite a 12% increase in sales of its narcolepsy treatment WAKIX, which generated $268.9 million. This profit fall was attributed to higher licensing costs and increased research and development spending. The company is reaffirming its full-year WAKIX revenue forecast and investing in experimental treatments like BP-205, while also defending its intellectual property.

Nov 4, 2026

Harmony Biosciences reported a third-quarter miss primarily due to increased royalty costs and decelerating growth of its WAKIX franchise, rather than a drop in demand. While patient additions remained steady, higher costs of products sold, attributed to new royalties, squeezed gross and operating margins. The company faces upcoming competitive pressure and crucial patent rulings in February 2027, adding execution uncertainty amidst a CEO transition.

Nov 4, 2026

Harmony Biosciences reported strong Q3 2026 financial results with WAKIX net revenue of $269 million, on track to exceed $1 billion for the year. The company announced a CEO transition, with Peter Anastasiou taking over in 2027, and highlighted promising preliminary Phase 1 data for its orexin 2 receptor agonist, BP205. Harmony is actively defending its WAKIX intellectual property through ongoing litigation and pursuing strategic acquisitions to expand its CNS market leadership.

Nov 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) reported Q3 earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share, and revenues of $268.92 million, also falling short of expectations. The company's stock has underperformed the S&P 500 year-to-date. Investors are now looking to future earnings outlook and management commentary for insights into the stock's potential movement.

Nov 1, 2026

Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) shows strong near-term sentiment with a mid-channel oscillation pattern, presenting an exceptional 51.0:1 risk-reward setup targeting a 15.0% gain. AI models suggest distinct trading strategies for various risk profiles, including long, breakout, and short positions based on multi-timeframe signal analysis. The stock exhibits a positive bias towards the long term.